Urgent

MOG antibody-associated disease (MOGAD)

Myelin oligodendrocyte glycoprotein antibody disease · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An inflammatory demyelinating disorder defined by serum MOG-IgG, presenting with optic neuritis, transverse myelitis, ADEM or brainstem syndromes. Distinct from MS and NMOSD, it is usually steroid-responsive but relapse-prone in a subset, requiring tailored immunotherapy.

Red flags

  • Severe bilateral or sequential optic neuritis with vision loss
  • Longitudinally extensive transverse myelitis with respiratory/sphincter involvement
  • Encephalopathy (ADEM-like)
  • Relapse during steroid taper
  • Diagnostic confusion with NMOSD (different treatment)

Assessment

Differential diagnosis

  • Multiple sclerosis
  • Neuromyelitis optica spectrum disorder (AQP4 antibody)
  • Acute disseminated encephalomyelitis
  • Infectious/para-infectious optic neuritis or myelitis
  • Sarcoidosis
  • Ischaemic optic neuropathy

Investigations

  • Serum MOG-IgG by cell-based assay (and AQP4-IgG to exclude NMOSD)
  • MRI brain, orbits and whole spine with contrast
  • Lumbar puncture (oligoclonal bands usually absent, unlike MS)
  • Visual acuity, fields and OCT for optic neuritis
  • Exclude infection and systemic inflammatory mimics
  • Repeat MOG-IgG after the acute phase to assess persistence

Management

  • Recognise optic neuritis, myelitis, ADEM or brainstem syndrome with supportive MRI
  • Send MOG-IgG and AQP4-IgG by cell-based assay before or alongside treatment
  • Treat the acute attack with high-dose intravenous corticosteroids
  • Add plasma exchange or IVIG for severe or steroid-refractory attacks
  • Taper oral steroids slowly, as rapid withdrawal can trigger relapse
  • Assess relapse risk (persistent MOG-IgG, relapsing course)
  • Start maintenance immunotherapy for relapsing disease
  • Avoid MS disease-modifying drugs which are ineffective or harmful in MOGAD
  • Monitor vision and neurological function longitudinally
  • Provide relapse-recognition advice and rapid access to care

Drugs & doses

Methylprednisolone 1 g IV daily for 3-5 days (acute attack)
Oral prednisolone taper over weeks to months after IV course
Plasma exchange (5-7 exchanges) for severe/refractory attacks
IVIG 2 g/kg for acute treatment or maintenance
Maintenance: rituximab, azathioprine, mycophenolate or regular IVIG for relapsing disease

Disposition

Specialist neuroimmunology/MS service. Acute admission for treatment. Long-term immunotherapy for relapsing disease.

Complications & pitfalls

  • Permanent visual loss
  • Residual myelopathy and bladder dysfunction
  • Relapse during or after steroid withdrawal
  • Immunosuppression-related infection
  • Cognitive sequelae after ADEM

Exam pearls

  • Low-titre or negative MOG-IgG should prompt caution; use a validated cell-based assay
  • Slow steroid tapers reduce early relapse risk
  • Do not use MS disease-modifying therapies (interferon, natalizumab) in MOGAD
  • Oligoclonal bands are usually absent, unlike multiple sclerosis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.